Interferon alpha association with neuromyelitis optica

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Asgari, Nasrin ^a,b   Voss, Anne ^c   Steenstrup, Troels ^b   Kyvik, Kirsten Ohm ^b,c   Stenager, Egon ^b,d,e   Thue Lillevang, Soeren ^c  

^a LILLEBAELT HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d Multiple Sclerosis Clinic of Southern Jutland   (Denmark)

^e Anæstesiologisk Center   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPANDED DISABILITY STATUS SCALE; FEMALE; HUMAN; MALE; MULTIPLE SCLEROSIS; MYELOOPTIC NEUROPATHY; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RELAPSE; REMISSION; ADOLESCENT; BLOOD; CASE CONTROL STUDY; IMMUNOLOGY; MIDDLE AGED; SYSTEMIC LUPUS ERYTHEMATOSUS; YOUNG ADULT;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; FEMALE; HUMANS; INTERFERON-ALPHA; INTERFERON-BETA; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NEUROMYELITIS OPTICA; YOUNG ADULT;

EID: 84890064895     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/713519     Document Type: Article

References (34)

1. Lassmann H., Targeting intracerebral inflammation in multiple sclerosis: is it feasible? Acta Neuropathol 2012 124 3 395 396
2. Lucchinetti C. F., Mandler R. N., McGavern D., Bruck W., Gleich G., Ransohoff R. M., Trebst C., Weinshenker B., Wingerchuk D., Parisi J. E., Lassmann H., A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 2002 125 part 7 1450 1461 2-s2.0-0036310181 (Pubitemid 34755161)
3. Lennon V. A., Kryzer T. J., Pittock S. J., Verkman A. S., Hinson S. R., IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. Journal of Experimental Medicine 2005 202 4 473 477 2-s2.0-23944444890 10.1084/jem.20050304 (Pubitemid 41186945)
4. Asgari N., Khorooshi R., Lillevang S. T., Owens T., Complement-dependent pathogenicity of brain-specific antibodies in cerebrospinal fluid. Journal of Neuroimmunology 2013 254 1-2 76 82
5. Asgari N., Owens T., Frøkiær J., Stenager E., Lillevang S. T., Kyvik K. O., Neuromyelitis optica (NMO)-an autoimmune disease of the central nervous system (CNS). Acta Neurologica Scandinavica 2011 123 6 369 384 2-s2.0-79954490726 10.1111/j.1600-0404.2010.01416.x
6. Benveniste E. N., Qin H., Type I interferons as anti-inflammatory mediators. Science Signaling 2007 2007 416, article pe70 2-s2.0-38449100329 10.1126/stke.4162007pe70
7. Arnason B. G., Immunologic therapy of multiple sclerosis. Annual Review of Medicine 1999 50 291 302 2-s2.0-0033017354 10.1146/annurev.med.50.1.291 (Pubitemid 29117068)
8. Teige I., Treschow A., Teige A., Mattsson R., Navikas V., Leanderson T., Holmdahl R., Issazadeh-Navikas S., IFN- β gene deletion leads to augmented and chronic demyelinating experimental autoimmune encephalomyelitis. Journal of Immunology 2003 170 9 4776 4784 2-s2.0-0037407587 (Pubitemid 36519987)
9. Prinz M., Schmidt H., Mildner A., Knobeloch K. P., Hanisch U. K., Raasch J., Merkler D., Detje C., Gutcher I., Mages J., Lang R., Martin R., Gold R., Becher B., Brück W., Kalinke U., Distinct and nonredundant in vivo functions of IFNAR on myeloid cells limit autoimmunity in the central nervous system. Immunity 2008 28 5 675 686 2-s2.0-43049177588 10.1016/j.immuni.2008.03. 011
10. Kim S. H., Kim W., Li X. F., Jung I. J., Kim H. J., Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Multiple Sclerosis Journal 2012 18 10 1480 1483
11. Tanaka M., Tanaka K., Komori M., Interferon- β 1b treatment in neuromyelitis optica. European Neurology 2009 62 3 167 170 2-s2.0-67649846243 10.1159/000227277
12. Khorooshi R., Wlodarczyk A., Asgari N., Owens T., Neuromyelitis optica-like pathology is dependent on type I interferon response. Experimental Neurology 2013 247 744 747 10.1016/j.expneurol.2013.02.005
13. Asgari N., Lillevang S. T., Skejoe H. P. B., Falah M., Stenager E., Kyvik K. O., A population-based study of neuromyelitis optica in Caucasians. Neurology 2011 76 18 1589 1595 2-s2.0-79955581259 10.1212/WNL.0b013e3182190f74
14. Wingerchuk D. M., Lennon V. A., Pittock S. J., Lucchinetti C. F., Weinshenker B. G., Revised diagnostic criteria for neuromyelitis optica. Neurology 2006 66 10 1485 1489 2-s2.0-33745334334 10.1212/01.wnl.0000216139. 44259.74 (Pubitemid 43958540)
15. Asgari N., Nielsen C., Stenager E., Kyvik K. O., Lillevang S. T., HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica. Multiple Sclerosis 2012 18 1 23 30 2-s2.0-84855952355 10.1177/1352458511417480
16. McDonald W. I., Compston A., Edan G., Goodkin D., Hartung H. P., Lublin F. D., McFarland H. F., Paty D. W., Polman C. H., Reingold S. C., Sandberg-Wollheim M., Sibley W., Thompson A., van den Noort S., Weinshenker B. Y., Wolinsky J. S., Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Annals of Neurology 2001 50 1 121 127 2-s2.0-0034955141 10.1002/ana.1032 (Pubitemid 32591472)
17. Barkhof F., Filippi M., Miller D. H., Scheltens P., Campi A., Polman C. H., Comi G., Adèr H. J., Losseff N., Valk J., Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 1997 120 part 11 2059 2069 2-s2.0-0030832846 10.1093/brain/120.11.2059 (Pubitemid 27493740)
18. Kurtzke J. F., Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983 33 11 1444 1452 2-s2.0-0021035886 (Pubitemid 14237132)
19. Jarius S., Frederikson J., Waters P., Paul F., Akman-Demir G., Marignier R., Franciotta D., Ruprecht K., Kuenz B., Rommer P., Kristoferitsch W., Wildemann B., Vincent A., Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. Journal of the Neurological Sciences 2010 298 1-2 158 162 2-s2.0-77958153790 10.1016/j.jns.2010.07.011
20. Borden E. C., Sen G. C., Uze G., Silverman R. H., Ransohoff R. M., Foster G. R., Stark G. R., Interferons at age 50: past, current and future impact on biomedicine. Nature Reviews Drug Discovery 2007 6 12 975 990 2-s2.0-36749069393 10.1038/nrd2422 (Pubitemid 350201788)
21. Theofilopoulos A. N., Baccala R., Beutler B., Kono D. H., Type I interferons (α / β) in immunity and autoimmunity. Annual Review of Immunology 2005 23 307 336 2-s2.0-17644402442 10.1146/annurev.immunol.23.021704. 115843 (Pubitemid 40563172)
22. Ivashkiv L. B., Type I interferon modulation of cellular responses to cytokines and infectious pathogens: potential role in SLE pathogenesis. Autoimmunity 2003 36 8 473 479 2-s2.0-0344665752 10.1080/08916930310001605882 (Pubitemid 37498243)
23. Banchereau J., Pascual V., Type I interferon in systemic lupus erythematosus and Other autoimmune diseases. Immunity 2006 25 3 383 392 2-s2.0-33748447541 10.1016/j.immuni.2006.08.010 (Pubitemid 44354221)
24. Borg F. A. Y., Isenberg D. A., Syndromes and complications of interferon therapy. Current Opinion in Rheumatology 2007 19 1 61 66 2-s2.0-33845357261 10.1097/BOR.0b013e328010c547 (Pubitemid 44885729)
25. Bitsch A., Dressel A., Meier K., Bogumil T., Deisenhammer F., Tumani H., Kitze B., Poser S., Weber F., Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. Journal of Neurology 2004 251 12 1498 1501 2-s2.0-12844284485 10.1007/s00415-004-0580-3 (Pubitemid 40169474)
26. Durelli L., Ferrero B., Oggero A., Verdun E., Bongioanni M. R., Gentile E., Isoardo G. L., Ricci A., Rota E., Bergamasco B., Durazzo M., Saracco G., Biava M. A., Brossa P. C., Giorda L., Pagni R., Aimo G., Autoimmune events during interferon beta-1b treatment for multiple sclerosis. Journal of the Neurological Sciences 1999 162 1 74 83 2-s2.0-0032945247 10.1016/S0022-510X(98) 00299-8 (Pubitemid 29064122)
27. Yamasaki M., Matsumoto K., Takahashi Y., Nakanishi H., Kawai Y., Miyamura M., Case of NMO (neuromyelitis optica) spectum disorder triggered by interferon alpha, which involved extensive pyramidal tract lesion of the brain. Rinsho Shinkeigaku 2012 52 1 19 24 2-s2.0-84856398930 10.5692/clinicalneurol.52.19
28. Roemer S. F., Parisi J. E., Lennon V. A., Benarroch E. E., Lassmann H., Bruck W., Mandler R. N., Weinshenker B. G., Pittock S. J., Wingerchuk D. M., Lucchinetti C. F., Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007 130 part 5 1194 1205 2-s2.0-34249650146 10.1093/brain/awl371 (Pubitemid 47355941)
29. Ishizu T., Osoegawa M., Mei F. J., Kikuchi H., Tanaka M., Takakura Y., Minohara M., Murai H., Mihara F., Taniwaki T., Kira J. I., Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 2005 128 part 5 988 1002 2-s2.0-21044448355 10.1093/brain/awh453 (Pubitemid 40675455)
30. Içöz S., Tüzün E., Kürtüncü M., Durmuş H., Mutlu M., Eraksoy M., Akman-Demir G., Enhanced IL-6 production in aquaporin-4 antibody positive neuromyelitis optica patients. International Journal of Neuroscience 2010 120 1 71 75 2-s2.0-76749157503 10.3109/ 00207450903428970
31. Feng X., Reder N. P., Yanamandala M., Hill A., Franek B. S., Niewold T. B., Reder A. T., Javed A., Type I interferon signature is high in lupus and neuromyelitis optica but low in multiple sclerosis. Journal of the Neurological Sciences 2012 313 1-2 48 53 2-s2.0-84855604535 10.1016/j.jns.2011.09.032
32. Palace J., Leite M. I., Nairne A., Vincent A., Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Archives of Neurology 2010 67 8 1016 1017 2-s2.0-77955456303 10.1001/archneurol.2010.188
33. Axtell R. C., de Jong B. A., Boniface K., van der Voort L. F., Bhat R., de Sarno P., Naves R., Han M., Zhong F., Castellanos J. G., Mair R., Christakos A., Kolkowitz I., Katz L., Killestein J., Polman C. H., de Waal Malefyt R., Steinman L., Raman C., T helper type 1 and 17 cells determine efficacy of interferon- Β in multiple sclerosis and experimental encephalomyelitis. Nature Medicine 2010 16 4 406 412 2-s2.0-77950534540 10.1038/nm.2110
34. Weinshenker B. G., Wingerchuk D. M., Pittock S. J., Lucchinetti C. F., Lennon V. A., NMO-IgG: a specific biomarker for neuromyelitis optica. Disease Markers 2006 22 4 197 206 2-s2.0-33751071376 (Pubitemid 44763273)